Leaflet TRUVADA 200mg / 245mg film-coated tablets
Indicated for: HIV-1 infection
Route of administration: oral
Substance: emtricitabine + tenofovir (nucleoside/nucleotide reverse transcriptase inhibitors)
ATC: J05AR03 (Antiinfectives for systemic use | Direct acting antivirals | Antivirals for treatment of HIV infections, combinations)
This medicine may affect the kidneys.
Use during breastfeeding only on medical advice.
Use during pregnancy only on medical advice.
The combination of emtricitabine and tenofovir is used for the treatment of human immunodeficiency virus (HIV) infection and for pre-exposure prophylaxis (PrEP) in individuals at high risk of infection. These drugs work by inhibiting reverse transcriptase, an enzyme essential for HIV replication.
The medication is taken orally, usually once daily, with the dose adjusted based on the patient's weight and renal function. Common side effects include nausea, diarrhea, headaches, and fatigue.
This combination is contraindicated in patients with severe renal impairment or hypersensitivity to any of the components. Its use also requires regular monitoring of renal and hepatic function.
This medication is an important option for managing HIV infection and preventing virus transmission, helping to improve patients' quality of life.
General data about TRUVADA 200mg / 245mg
- Substance: emtricitabine + tenofovir
- Date of latest medicines list: 01-07-2013
- Product code: W51766001
- Concentration: 200mg / 245mg
- Pharmaceutical form: film-coated tablets
- Quantity: 30
- Product type: Original
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.